|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
1972
|
|
gptkbp:ATCCode
|
gptkb:N05AH02
|
|
gptkbp:bioavailability
|
60-70%
|
|
gptkbp:CASNumber
|
gptkb:13587-41-6
|
|
gptkbp:contraindication
|
history of agranulocytosis
severe central nervous system depression
|
|
gptkbp:eliminationHalfLife
|
8-12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
LGCZFYXIUMFQPL-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C18H19ClN4
|
|
gptkbp:hasSMILES
|
CN1CCN(CC1)C2=Nc3ccc(Cl)cc3Nc4ccccc24
|
|
gptkbp:hasUNII
|
J60AR2IKIC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
13587-41-6
|
|
gptkbp:IUPACName
|
8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Novartis
|
|
gptkbp:meltingPoint
|
183-184°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
326.82 g/mol
|
|
gptkbp:name
|
gptkb:Clozapine
|
|
gptkbp:pregnancyCategory
|
C (US)
B (Australia)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:DB00363
2818
CHEMBL45
|
|
gptkbp:riskFactor
|
gptkb:orthostatic_hypotension
gptkb:diabetes_mellitus
gptkb:metabolic_syndrome
constipation
neutropenia
tachycardia
sudden cardiac death
dyslipidemia
hypersalivation
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
constipation
weight gain
seizures
drowsiness
myocarditis
agranulocytosis
|
|
gptkbp:synonym
|
gptkb:Denzapine
gptkb:FazaClo
gptkb:Versacloz
gptkb:Clozaril
Leponex
|
|
gptkbp:usedFor
|
gptkb:schizoaffective_disorder
schizophrenia
antipsychotic medication
treatment-resistant schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:ND3
|
|
gptkbp:bfsLayer
|
7
|